Infinity, Sarepta planning follow-ons

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) both proposed follow-ons late Wednesday. Infinity's follow-on is underwritten by Morgan Stanley; JPMorgan; BofA Merrill Lynch; Deutsche Bank; and Stifel Nicolaus Weisel. Infinity has two compounds in Phase II testing: IPI-145, an oral delta and gamma inhibitor of phosphoinositide-3-kinase ( PI3K) for asthma; and retaspimycin ( IPI-504), a small molecule heat shock protein 90 (Hsp90) chaperone inhibitor for non-small cell lung cancer.

Lazard is the underwriter for Sarepta, which is developing eteplirsen for Duchenne muscular dystrophy (DMD). The phosphorodiamidate morpholino oligomer (PMO) targeting exon 51 is in Phase II testing for the indication (see BioCentury Extra, Oct. 3). ...